Skip to main content
STVN
NYSE Industrial Applications And Services

Stevanato Group Reports Strong Q1 Results, Reaffirms FY26 Guidance on High-Value Solutions Demand

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Instrument Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$18.03
Mkt Cap
$4.922B
52W Low
$12.89
52W High
$28
52W Position info
40% above low
Off High info
36% below high
Rel. Volume info
1.5× avg
Market data snapshot near publication time

STVN sits 40% above its 52-week low of $12.89.

Summary

Stevanato Group reported a 7% revenue increase and 14% Adjusted EBITDA growth in Q1 2026, driven by strong demand for high-value solutions, and reaffirmed its full-year guidance.


Key Events · Earnings and Guidance · STVN

  • Strong Q1 2026 Financial Performance

    Revenue increased 7% (10% at constant currency) to €273.6 million, with Adjusted EBITDA growing 14% to €65.5 million.

  • Reiterated FY 2026 Guidance

    The company reaffirmed its full-year revenue guidance of €1.26 billion - €1.29 billion and Adjusted Diluted EPS of €0.59 - €0.63, indicating confidence in future performance.

  • High-Value Solutions (HVS) Driving Growth

    HVS revenue grew 17% (22% at constant currency) to €129 million, fueled by a 20% increase in Pre-fillable Syringes (PFS) demand and GLP1s contributing 21-22% of total revenue.

  • Capacity Expansion Progress

    Ramp-up continues at new facilities in Latina, Italy, for EZ-fill® cartridges (commercial production by early 2027) and Fishers, U.S., for DDS contract manufacturing (commercial production by late 2026/early 2027).


Analysis · STVN · Industrial Applications And Services

Stevanato Group delivered solid first-quarter results, driven by robust demand for its high-value biopharmaceutical solutions, particularly pre-fillable syringes and GLP1-related products. The reiteration of full-year guidance signals management's confidence in continued growth and operational execution, despite a higher tax rate and increased capital expenditures for capacity expansion. The strategic focus on high-growth markets and efficiency improvements in the Engineering segment are key takeaways for investors.

At the time of this filing, STVN was trading at $18.03 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $4.9B. The 52-week trading range was $12.89 to $28.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

STVN - Latest Insights

STVN
May 15, 2026, 4:47 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $17.99
Real-time Price: $19.68 info
Change: +$1.69 (+9%) info
Market Cap: $5.373B info
STVN
May 11, 2026, 9:28 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $18.29
Real-time Price: $19.68 info
Change: +$1.39 (+8%) info
Market Cap: $5.373B info
STVN
May 07, 2026, 4:20 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $18.03
Real-time Price: $19.68 info
Change: +$1.65 (+9%) info
Market Cap: $5.373B info
STVN
May 07, 2026, 4:11 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $18.03
Real-time Price: $19.68 info
Change: +$1.65 (+9%) info
Market Cap: $5.373B info
STVN
May 07, 2026, 6:37 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $19.60
Real-time Price: $19.68 info
Change: +$0.0808 (+0.41%) info
Market Cap: $5.373B info